Accelerate Diagnostics (NASDAQ:AXDX) Seems Tp Be A Stock That Piper Jaffray Is Interested In


How Piper Jaffray Currently Rates Accelerate Diagnostics (NASDAQ:AXDX)

The Investment firm Piper Jaffray has have initiated coverage on Accelerate Diagnostics (NASDAQ:AXDX)’s stock, rating it “Overweight”. This was sent to clients and investors in an analyst note on 16 December.

Approximately 66,017 shares of stock traded hands. Accelerate Diagnostics Inc (NASDAQ:AXDX) has declined 2.67% since May 13, 2015 and is downtrending. It has underperformed by 0.04% the S&P500.

The overall sentiment of institutions has increased to 1.31 in Q2 2015. Its up 0.04, from 1.27 in 2015Q2. The ratio improved, as 12 institutions have sold all the shares of Accelerate Diagnostics Inc that they owned while 20 funds have taken shares off the table. 12 funds have purchased shares for the first time while 30 added to their positions. These institutions now hold 17.15 million shares or 71.90% more than the 9.98 million shares they owned in 2015Q2.

The Fund Birchview Capital Lp currently is holding shares equating to 28.19% of its total portfolio in Accelerate Diagnostics Inc representing a total of 2.07 million shares. Another fund,Selkirk Management Llc, is holding a total of 245,017 shares equating to 2.46% of their holdings. Additionally, Iguana Healthcare Management Llc has a 150,000 share stake in Accelerate Diagnostics Inc which represents 0.95% of their total portfolio. The Fund, Opaleye Management Inc., based out of Massachusetts, has also built up a stake in the stock, which represents a total of 0.76% of their total portfolio. Finally Dsc Advisors L.P., a fund which is based in the state of Illinois reported a total holdings of 95,000 shares.

Insider activity is a very important aspect to track on any stock. Going back to March 9, 2015, shareholders of Accelerate Diagnostics Inc have witnessed 4 buys, and a total of 0 insider sales equating to a net activity of approximately $808,978 . Schuler Jack W bought 2,160 shares worth approximately $34,180. Reichling Steven bought 600 shares worth approximately $9,138. Ten Brink Frank Jm bought 9,800 shares worth approximately $149,352. Strobeck Matthew bought 2,000 shares worth approximately $44,080. The company insider Mehren Lawrence bought 500 shares worth $10,240.

Accelerate Diagnostics, Inc. is an in-vitro diagnostics firm providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The company has a market cap of $1.10 billion. The Firm is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather than the two to three days required to deliver identification and susceptibility results. It currently has negative earnings. It has developed a diagnostic platform, the Accelerate ID/AST System , intended for the rapid diagnosis of infectious pathogens.

According to Zacks Investment Research, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado.”